Management of macroprolactinoma in pregnancy Makroprolaktinoma ve gebelikte klinik yaklaşim


ÇEPNİ İ. , ULUDAĞ S., VURAL A. M. , ÖÇAL K. P. , Idil M., AKSU M.

Jinekoloji ve Obstetrik Dergisi, cilt.15, sa.1, ss.59-61, 2001 (Diğer Kurumların Hakemli Dergileri) identifier

  • Cilt numarası: 15 Konu: 1
  • Basım Tarihi: 2001
  • Dergi Adı: Jinekoloji ve Obstetrik Dergisi
  • Sayfa Sayıları: ss.59-61

Özet

Treatment of macroprolactinoma during pregnancy is still controversial. Due to hormonal milleu of pregnancy tumor enlargement can be seen and dopaminergic agents (bromocriptine) may have teratogenic effects on fetus. We reported two women who became pregnant after bromocriptine therapy. First case continued bromocriptine therapy during the pregnancy and no tumor enlargement was detected. The second case stopped taking bromocriptine after her symptoms improved and afterwards she became pregnant. At the 20th weeks of gestation bromocriptine therapy was reintroduced since the enlargement of the tumor reoccurred. She continued her treatment at the rest of the pregnancy. In both cases no teratogenic effects of bromocriptine was observed. After pregnancy in the control MRI of patients there were obvious regression in the tumor sizes. In order to prevent complications of macroprolactinoma during pregnancy bromocriptine treatment is necessary and helpful.